Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

NCT02317796 is registered in ClinicalTrials.gov with Melior Pharmaceuticals as lead sponsor.

NCT NCT02317796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02317796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes
Lead sponsor
Melior Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
February 29, 2016
Enrollment
149 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes